Increase in Q4 on Q3 revenue was only about 5% though.. which isn't shooting the lights off. Th eissue is how much is covid related (reduction in optional surgery) or prioritisation of hospital resourceS? I'd imagine if you needed the surgery done (urgently) then it is unaffected and this is a good way of demonstrating how much penetration there is of the products.
Where it probably falls short in the whole covid process is the fact that sales and training representation would be affected by the limitations imposted by Covid 19. So there is going to be some impact... but yeah would have loved to see a higher % gain on revenue for the quarter to maintain momentum. The corporate and admin costs vs staff costs are burning a hole in the pocket, but if they can raise revenue another 400-600k a quarter and get cashflow neutral that would be a huge improvement in the trajectory.
- Forums
- ASX - By Stock
- Ann: Activities Update Qtr Ending December 2020 and Appendix 4C
OSX
osteopore limited
Add to My Watchlist
0.00%
!
1.2¢

Increase in Q4 on Q3 revenue was only about 5% though.. which...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.081M |
Open | High | Low | Value | Volume |
1.3¢ | 1.3¢ | 1.2¢ | $13.22K | 1.094M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 446472 | 1.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.3¢ | 557877 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 446472 | 0.012 |
7 | 954411 | 0.011 |
7 | 1050000 | 0.010 |
4 | 317111 | 0.009 |
3 | 275001 | 0.008 |
Price($) | Vol. | No. |
---|---|---|
0.013 | 557877 | 3 |
0.014 | 1120133 | 4 |
0.015 | 194010 | 1 |
0.016 | 759159 | 3 |
0.017 | 160000 | 2 |
Last trade - 15.25pm 18/06/2025 (20 minute delay) ? |
Featured News
OSX (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online